Seres Therapeutics (MCRB) Misses Q3 EPS by 25c

Seres Therapeutics (NASDAQ: MCRB) reported Q3 EPS of ($0.33), $0.25 worse than the analyst estimate of ($0.08).

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Morgan Stanley Downgrades Sims Metal Management Ltd. (SGM:AU) (SMUPF) to Underweight